HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate

By HospiMedica International staff writers
Posted on 20 May 2020
Print article
Image: Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate (Photo courtesy of Johnson & Johnson)
Image: Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate (Photo courtesy of Johnson & Johnson)
Vibalogics GmbH (Cuxhaven, Germany) will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by Johnson & Johnson’s (New Brunswick, NJ, USA) Janssen Pharmaceutical Companies (Beerse, Belgium).

Vibalogics, a global contract development and manufacturing organization that specializes in the production of virotherapy products, is contracted to manufacture multiple batches, which will result in many thousands of doses of an investigational COVID-19 vaccine candidate. Vibalogics will carry out the production at its GMP-accredited facility in Germany where it has recently invested in new equipment to handle larger clinical batches, including a new filling line capable of filling and labeling more than 30,000 vials per batch. Vibalogics is also set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines in the near future.

“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and CEO of Vibalogics. “The business has reacted quickly and efficiently to accommodate this request. With the devotion of our team, and understanding from our customers, we have successfully managed to fulfill this new requirement alongside all of our existing business commitments.”

“This is a fantastic opportunity for the business and our employees to strengthen our position as a global leader in virotherapy manufacturing whilst also providing a key service to our valued customer in its mission to combat the SARS-CoV-2 virus,” added Beyer. “This endeavor is testament to our long-standing and productive partnership with this company, who have shown great trust in our flexible approach, expertise and ability to deliver on time.”

Related Links:
Johnson & Johnson
Janssen Pharmaceutical Companies
Vibalogics GmbH


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ultrasound System
Voluson Signature 18

Print article

Channels

Critical Care

view channel
Image: The new risk assessment tool determines patient-specific risks of developing unfavorable outcomes with heart failure (Photo courtesy of 123RF)

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

Heart failure is a serious condition where the heart cannot pump sufficient blood to meet the body's needs, leading to symptoms like fatigue, weakness, and swelling in the legs and feet, and it can ultimately... Read more

Surgical Techniques

view channel
Image: The multi-sensing device can be implanted into blood vessels to help physicians deliver timely treatment (Photo courtesy of IIT)

Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health

Researchers have embarked on a project to develop a multi-sensing device that can be implanted into blood vessels like peripheral veins or arteries to monitor a range of bodily parameters and overall health status.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more